Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SKB 571

Next Previous
X
Search
Drug Profile

SKB 571

Alternative Names: SKB-571

Latest Information Update: 08 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Kelun Pharmaceutical Research Institute
  • Developer Merck & Co; Sichuan Kelun Pharmaceutical Research Institute
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 10 Dec 2024 Preclinical trials in Solid tumours in China (Parenteral) prior to December 2024 (Sichuan Kelun Pharmaceutical Research Institute Pipeline, December 2024)
  • 10 Dec 2024 Sichuan Kelun Pharmaceutical Research Institute plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) (Parenteral, Injection) (NCT06725381)
  • 30 Nov 2024 The NMPA China approves the Investigational New Drug (IND) application of Kelun Pharmaceutical Research Institute for the treatment of Solid tumours (Sichuan Kelun Pharmaceutical Research Institute Pipeline, December 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top